<SEC-DOCUMENT>0000950103-22-010167.txt : 20220607
<SEC-HEADER>0000950103-22-010167.hdr.sgml : 20220607
<ACCEPTANCE-DATETIME>20220607070539
ACCESSION NUMBER:		0000950103-22-010167
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20220607
FILED AS OF DATE:		20220607
DATE AS OF CHANGE:		20220607

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Immatics N.V.
		CENTRAL INDEX KEY:			0001809196
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			P7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39363
		FILM NUMBER:		22999797

	BUSINESS ADDRESS:	
		STREET 1:		PAUL EHRLICH-STRASSE 15
		CITY:			TUBINGEN
		STATE:			2M
		ZIP:			72076
		BUSINESS PHONE:		49 7071 5397 700

	MAIL ADDRESS:	
		STREET 1:		PAUL EHRLICH-STRASSE 15
		CITY:			TUBINGEN
		STATE:			2M
		ZIP:			72076

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Immatics B.V.
		DATE OF NAME CHANGE:	20200413
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>dp174802_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">



<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B>&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B>&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 6-K</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.85pt; text-align: center; text-indent: -6.85pt"><B>REPORT OF FOREIGN
PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR<BR>
15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.85pt; text-align: center; text-indent: -6.85pt">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">June 7, 2022&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Commission File Number: 001-39363</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 22pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>IMMATICS N.V.</B></P>

<P STYLE="font: 22pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Paul-Ehrlich-Stra&szlig;e 15&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>72076 T&uuml;bingen, Federal Republic of Germany&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Address of principal executive office)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Indicate by check mark whether the registrant files
or will file annual reports under cover of Form 20-F or Form 40-F:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 80%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Form 20-F</FONT></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: black 0.5pt solid">&#9746;&nbsp;</P></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Form 40-F</FONT></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: black 0.5pt solid">&#9744;</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(1): <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(7): <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INFORMATION CONTAINED IN THIS REPORT ON FORM
6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On June 7, 2022, Immatics N.V. (the &ldquo;Company&rdquo;
or &ldquo;Immatics&rdquo;) announced that it entered into a strategic research collaboration and licensing agreement with Editas Medicine,
Inc. (&ldquo;Editas Medicine&rdquo;), a leading genome editing company, to combine gamma-delta T cell adoptive cell therapies and gene
editing to develop medicines for the treatment of cancer. As part of the licensing agreement, Immatics gains non-exclusive rights to Editas
Medicine&rsquo;s CRISPR technology and intellectual property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In connection with the foregoing, the Company issued
a press release, a copy of which is attached hereto as Exhibit 99.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INCORPORATION BY REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This Report on Form 6-K (other than Exhibit 99.1)
shall be deemed to be incorporated by reference into the registration statements on Form F-3 (Registration Nos. 333-258351 and 333-240260)
of Immatics N.V. and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports
subsequently filed or furnished.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"><B>Exhibit No.</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Press release dated June 7, 2022</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>IMMATICS N.V.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Date: June 7, 2022</FONT></TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Harpreet Singh</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Harpreet Singh</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"></P>


<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>dp174802_ex9901.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%">&nbsp;<IMG SRC="image_001.jpg" ALT=""></TD>
  <TD STYLE="text-align: right; width: 50%"><IMG SRC="image_002.jpg" ALT="">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 18pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>PRESS RELEASE</B></FONT></P>

<P STYLE="font: 18pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>Immatics and Editas
Medicine Enter Strategic Research Collaboration and Licensing Agreement to Combine Gamma-Delta T Cell Adoptive Cell Therapies and Gene
Editing for the Treatment of Cancer</B></FONT></P>

<P STYLE="font: 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Tuebingen, Germany;
Houston, Texas; and Cambridge, Mass., June 7, 2022 </B>&ndash; Immatics N.V. (Nasdaq: IMTX, &ldquo;Immatics&rdquo;), a clinical-stage
biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, and Editas Medicine,
Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that the two companies have entered into a strategic research
collaboration and licensing agreement to combine gamma-delta T cell adoptive cell therapies and gene editing to develop medicines for
the treatment of cancer. As part of the licensing agreement, Immatics gains non-exclusive rights to Editas Medicine&rsquo;s CRISPR technology
and intellectual property. Editas Medicine is the exclusive licensee of Harvard and Broad Institute&rsquo;s Cas9 patent estates and Broad
Institute&rsquo;s Cas12a patent estate for human medicines.</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">By
combining Editas Medicine&rsquo;s gene editing technology with Immatics&rsquo; <FONT STYLE="color: #252525">ACTallo&reg; </FONT></FONT><FONT STYLE="font-size: 10pt">allogeneic,
off-the-shelf adoptive cell therapy platform based on gamma-delta T cells, gamma-delta T cells can be redirected to cancer cell targets
with the goal of creating cells with enhanced tumor recognition and destruction.</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;Engineered
cell therapies have the potential to significantly impact the treatment paradigm for cancer, and our partnership with the esteemed team
at Editas Medicine will provide us with further versatility and flexibility in how we engineer our <FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; color: #252525">ACTallo&reg;
cell therapies based on a specific tumor target</FONT>,&rdquo; said Rainer Kramer, Ph.D., Chief Business Officer, Immatics. &ldquo;It
has always been our focus to deliver innovative science to cancer patients and this collaboration with Editas Medicine will enable us
to access CRISPR technologies and apply them to our off-the-shelf gamma-delta T cell platform.&rdquo;</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;We believe
that our gene editing technology can modulate and enhance the potential of cell therapies to deliver transformative medicines for the
treatment of cancer. We are excited to work with the team at Immatics to develop new experimental medicines with enhanced tumor fighting
abilities to help patients with cancer,&rdquo; said Gilmore O&rsquo;Neill<FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">, </FONT>M.B.,
M.M.Sc., President and Chief Executive Officer, Editas Medicine.</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Under the terms
of the agreement, Editas Medicine will be eligible to receive an undisclosed upfront cash payment as well as additional milestone payments
based on development, regulatory, and commercial milestones. In addition, Immatics will pay royalties on future net sales on any products
that may result from this collaboration.</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">-END-</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;<IMG SRC="image_001.jpg" ALT=""></TD><TD STYLE="text-align: right; width: 50%"><IMG SRC="image_002.jpg" ALT="">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>About Immatics</B></FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Immatics combines
the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling
a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies
and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the
power of T cells and to unlocking new avenues for patients in their fight against cancer.</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">For regular updates
about Immatics, visit www.immatics.com. You can also follow us on Instagram, Twitter and LinkedIn.</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>About Editas
Medicine</B></FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">As a leading genome
editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a genome editing
systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover,
develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. Editas Medicine
is the exclusive licensee of Harvard and Broad Institute&rsquo;s Cas9 patent estates and Broad Institute&rsquo;s Cas12a patent estate
for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com.</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Immatics Forward-Looking
Statements</B></FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Certain statements
in this press release may be considered forward-looking statements. Forward-looking statements generally relate to future events or Immatics&rsquo;
future financial or operating performance. For example, statements concerning the timing of product candidates and Immatics&rsquo; focus
on partnerships to advance its strategy are forward-looking statements. In some cases, you can identify forward-looking statements by
terminology such as &ldquo;may&rdquo;, &ldquo;should&rdquo;, &ldquo;expect&rdquo;, &ldquo;intend&rdquo;, &ldquo;will&rdquo;, &ldquo;estimate&rdquo;,
&ldquo;anticipate&rdquo;, &ldquo;believe&rdquo;, &ldquo;predict&rdquo;, &ldquo;potential&rdquo; or &ldquo;continue&rdquo;, or the negatives
of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and
other factors which could cause actual results to differ materially from those expressed or implied by such forward looking statements.
These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Immatics and its management,
are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties.
Factors that may cause actual results to differ materially from current expectations include, but are not limited to, various factors
beyond management's control including general economic conditions and other risks, uncertainties and factors set forth in filings with
the SEC. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth
herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place
undue reliance on forward-looking statements, which speak only as of the date they are made. Immatics undertakes no duty to update these
forward-looking statements.</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;<IMG SRC="image_001.jpg" ALT=""></TD><TD STYLE="text-align: right; width: 50%"><IMG SRC="image_002.jpg" ALT="">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Editas Forward-Looking
Statement</B></FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">This press release
contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995. The words
&lsquo;&lsquo;anticipate,&rsquo;&rsquo; &lsquo;&lsquo;believe,&rsquo;&rsquo; &lsquo;&lsquo;continue,&rsquo;&rsquo; &lsquo;&lsquo;could,&rsquo;&rsquo;
&lsquo;&lsquo;estimate,&rsquo;&rsquo; &lsquo;&lsquo;expect,&rsquo;&rsquo; &lsquo;&lsquo;intend,&rsquo;&rsquo; &lsquo;&lsquo;may,&rsquo;&rsquo;
&lsquo;&lsquo;plan,&rsquo;&rsquo; &lsquo;&lsquo;potential,&rsquo;&rsquo; &lsquo;&lsquo;predict,&rsquo;&rsquo; &lsquo;&lsquo;project,&rsquo;&rsquo;
&lsquo;&lsquo;target,&rsquo;&rsquo; &lsquo;&lsquo;should,&rsquo;&rsquo; &lsquo;&lsquo;would,&rsquo;&rsquo; and similar expressions are
intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking
statements in this press release include statements regarding the expected benefits of Editas Medicine&rsquo;s collaboration with Immatics,
including any future payments it may receive under the strategic research collaboration and licensing agreement and the potential to
generate medicines from the collaboration. Editas Medicine may not actually achieve the plans, intentions, or expectations disclosed
in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events
could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various
factors, including: uncertainties inherent in the initiation and completion of pre-clinical studies and clinical trials and clinical
development of Editas Medicine&rsquo;s product candidates; availability and timing of results from pre-clinical studies and clinical
trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials;
expectations for regulatory approvals to conduct trials or to market products and availability of funding sufficient for Editas Medicine&rsquo;s
foreseeable and unforeseeable operating expenses and capital expenditure requirements. These and other risks are described in greater
detail under the caption &ldquo;Risk Factors&rdquo; included in Editas Medicine&rsquo;s most recent Annual Report on Form 10-K, which
is on file with the Securities and Exchange Commission, as updated by Editas Medicine&rsquo;s subsequent filings with the Securities
and Exchange Commission, and in other filings that Editas Medicine may make with the Securities and Exchange Commission in the future.
Any forward-looking statements contained in this press release represent Editas Medicine&rsquo;s views only as of the date hereof and
should not be relied upon as representing its views as of any subsequent date. Except as required by law, Editas Medicine explicitly
disclaims any obligation to update any forward-looking statements.</FONT>&nbsp;</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;<IMG SRC="image_001.jpg" ALT=""></TD><TD STYLE="text-align: right; width: 50%"><IMG SRC="image_002.jpg" ALT="">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>For more information,
please contact:</B></FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; text-align: justify; font-size: 12pt"><FONT STYLE="font-size: 10pt">Immatics Media and Investor Relations</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 12pt"><FONT STYLE="font-size: 10pt">Jacob Verghese or Stephanie May</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 12pt"><FONT STYLE="font-size: 10pt">Trophic Communications</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 12pt"><FONT STYLE="font-size: 10pt">Phone: +49 89 2070 89831</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 12pt"><FONT STYLE="font-size: 10pt; color: Blue"><U>immatics@trophic.eu</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%; text-align: justify"><FONT STYLE="font-size: 10pt">Immatics N.V.</FONT></TD>
    <TD STYLE="width: 49%; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Anja Heuer</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Jordan Silverstein</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Director, Corporate Communications</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Head of Strategy</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Phone: +49 89 540415 606</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Phone: +1 281 810 7545</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; color: Blue"><U>media@immatics.com</U></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; color: Blue"><U>InvestorRelations@immatics.com</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%; text-align: justify; font-size: 12pt"><FONT STYLE="font-size: 10pt">Editas Medicine</FONT></TD>
    <TD STYLE="width: 49%; text-align: justify; font-size: 12pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Media</FONT></P>
    <P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Cristi Barnett</FONT></P>
    <P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">+1 617 401 0113</FONT></P>
    <P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt; color: Blue"><U>Cristi.barnett@editasmed.com</U></FONT></P></TD>
    <TD><P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Investors</FONT></P>
    <P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Ron Moldaver</FONT></P>
    <P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">+1 617 401 9052</FONT></P>
    <P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt; color: Blue"><U>ir@editasmed.com</U></FONT></P></TD></TR>
  </TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !( *\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBJ6I:Q
MINCP>=J5];VD9Z&:0+GZ9Z_A0!=HKG=-\=>&=7NGMK#5X9IE&XH%8$COC(Y_
M"MV&Z@N/]3,CXZA3R*AU(*7(VK]NH^5VO;0EHHJ.>XAM8&GN)HX8D&6DD8*J
MCW)JQ$E%<I/\2_!MO(8WUZW+#O&KN/S4$5KZ3XCT;75)TO4[:Z(Y*QN-P^J]
M1^5 'A?QJED3QX DC*/L<? ..[5Z@[/_ ,*2W*6W_P!A@@@\Y\JO+/C;_P C
M\O\ UYQ_S:O;/"D\5MX"T:>>1(H8].A9W=@%4!!DDGH*0'FOP9\4ZQ=:M<:)
MJ$\]Q;>0986F)8QE2!@$\X(/3VKT'Q[XGN/"/AO^U+:WBGD\Y(]DA(&#GGCZ
M5KV.O:/J4Y@L-4LKJ8*6\N"=7;'K@'I7G?Q?UW2+_P $M;6>J65Q.+J,F**=
M688SG@'- &[\./&]WXUM;^:[M(+<VSHJB(DYR"><_2NXKQ'X):SI>EZ?JZZA
MJ-I:,\L903S*A8 -G&3S7L=AJFGZHCOI]];7:(<,T$JN%/H<&F!;HJAJ>N:5
MHR!]2U&VM WW?.D"EOH.IK /Q/\ !BOM.NPY]HY"/SVT ==163I7B?0]<;9I
MFJVMS(!GRTD&_'^Z>:UJ "BJ][?V>G6[7%]=0VT*]9)G"+^9KFI/B;X-BD*-
MKL!(_NQNP_,+B@#K:*QM+\6^']:D$6G:O:3RGI&) '/_  $\ULT <7\1?'<7
M@W2E6!4EU.Y!$$;=$'=V]AZ=S^->':5H/BGXD:M-<AY+E@<2W=R^(T]L_P#L
MH'X5+XRN[GQ?\3;FWB;<7NQ96X/0*&V#\,Y/XFOHW2M,T[POH,-E;^7!9VL?
MS2.0H_VG8^IZDT@/(X/@;J]FT=U:^(+>.\B(="L;+M8=,-G/Z5U,3WT=N'N_
M*BU.V<17B6\@90^,JXQT##G! P<CTKF?'7QC9_,TWPNY5>5DOR.3_P!<QV_W
MC^'K4WPM\'^((8=1U'4LPVNH086*?/F2OG<LA],<]>3D_6N#,<''%4''[2U3
M[/\ X.QTX6LZ51-[=?0]#T_Q-&-,NIKW<6M(6F<HN2ZJ,G '>O -=\1>(/B/
MXBCM8ED=9)"MK8QGY4'J>Q..2Q_05ZI:7365\DN.4;E3W'<?EQ5OP#X*MO#_
M (G\07T<>8VD5+)L<+"P#G'YJO\ P&N7)<;/$47"H[RC^*Z?Y'1F&&5&:E'9
MG+:;\!9'ME?4]:$<Y',=O#N"_P# B1G\JRO$/PDUSPO&=6T2_:\6V_>$Q*8Y
MHP.X )SCV.?:OH&BO9L><?(WB7Q)=>*+VVO;X+]JCME@D<?\M"I/S8[$@C->
M_P G_)#S_P!@(?\ HFO%OB;HD6@^.KZ"W0);S8N(U P%##) ]MVZO:I/^2'_
M /<"'_HF@9Y?\$/^1\E_Z\9/_0DJ#QM\,;WPOIDVLSZC;S1O.%\M$8'YB3WJ
M?X(?\CY+_P!>,G_H25Z+\:O^2?G_ *^X_P"M 'D?@GX>W?C:WNYK:^@MA;.J
MD2*3G()[?2N],%W\&_!5]F[@NK_4)U6U**<(0IRQ!ZX'ZD4_X!_\@W6O^NT7
M\FKN?%_@;3?&GV0:C<7<8M=^P0.H!W8SG(/]T4"/"?#'@O7_ (BWMS?R7>(@
M^)KRY8L2W7 '<XQQP!Q7=_\ "@[7RL?V_-YF.OV88S]-U>E>&O#EEX4T5-,L
M6D:!&9R\I!8DG)R0!_D5)>>)="T_/VO6+"$CJ'N%!_+.:+ ?-GB[P9JW@/4[
M<R3[XY"6M[N E<D=?=6&1_C7MG@SQL;_ .&TFNZD2\VGI(MP1P9"@R#]2"OX
MFO/OB[XYT?Q';6>F:3(;D03&62X"D+G! 49Y/7KTX'6M?X;:7+K7P?U[3H"!
M-<32I'GH6\M,#\\4#//S-XA^*'BU83+YD\I)1&8B*WC'7'H!^9]R:[^W^ <7
MDC[3K[^;CGR[;Y1^;<UYOX3\177@?Q4+U[4LT>Z"XMY/E;:3R/8@@?E7O6D?
M%7PEJR+G4A9RGK'=KLQ_P+[OZT >.^,OACJW@ZW&HQW*WEBK &>-2C1'/!9>
M<<]P>OI7I?P@\9W7B'2[C3-2E,MY9!2DK'+21GCGU(/&?<5W5S#I?B72)[1Y
M8;RRN%V2>5*""/JIK,\/^!/#_A>^DO-)M)(9I(S$Q,SN"I(/0GU H$?.VGWB
M>&OB(MU?J[K8W[F4*,L=K'./>MCQ!XN\2?$O5ETRPMY!;,V8K& \8'\3GOCU
M. *N_&3PM+I7B8ZS#&?L6H'<6 X24#Y@?KC=^?I77_!_Q#X972%TR.*"PU?I
M*9&YN?0ACU_W>W:@9H^!?A/8>'?+U#5O+O=3&"JXS%"?8'[Q]S^ [UZ02 "2
M< 4$X&3TKR[XE_$NRTS3+C1]'N4N-1G4QR21-E8%/!Y'\7; Z=?JQ#]=$::F
M\UNZO;W"B>)UZ,K#((]J[7PO>"[T.+)RT1,9_#I^A%>7>%);O6/AQ;7$D$@;
M3)6MA(1Q)%U4CUVD[:Z;P9JRVNHM:2MB.XP%)[,.GY]/RKYJBOJ>9-/2,OUU
M7XZ'OU(_6L I+>/Z;_AJ>B44 @]#FL[6M<T_P]ILM_J5PL,*#C)^9S_=4=S[
M5]*> >#?&Z5)/'D:KC,=E&K?7<Q_D17J,G_)#_\ N!#_ -$U\]^)-;F\1^(;
MW5IQM:XDW!<YV*.%7\  *^A)/^2'_P#<"'_HFD,\O^"'_(^2_P#7C)_Z$E>B
M_&K_ ))^?^ON/^M>=?!#_D?)?^O&3_T)*]%^-7_)/V_Z^X_ZT 8?P#_Y!NM?
M]=HOY-70_$OXA'P?;0V=BB2:G<J67?RL2=-Q'<DYP/8_0\U\!)XOLFM0>8OG
M>9$X3/)&&&<5RGQH64?$&0R9VFVB,>?[N#_7-'00[1_#WCCXDJUY<:E+]A+%
M?.NI2L9/<(@Z_@ />NHL_@)" #>Z](Q[K#;A?U+'^5=W\.;ZRO? 6D?8G0B&
MW6*55ZI(!\P(]<\^^<UU+,J*6=@J@9))P *+ >!?$OP#HO@[PS8RZ>)Y+F6Z
MV/-,^25V,<8& .?:NP^!G_(DW?\ U_O_ .@)7&?&+QG9:]>6NDZ9*L]M9LSR
MS*<J\AXPI[@#//?/M5WP3<ZE;_!?7;C1YWAOK6\,H9 "=H6,MU_V<_E0,],\
M3?#_ ,/>*G,U_:%+K&/M,!V/^/8_B#7G>I? 64;FTO6T;T2YB(_\>4G^5)\+
M_B3=W.MSZ?XDU5I%N%46TDVU55P3E<@#&<]_3WKVV@1\N:OX,\7>"7^VM'/#
M&A_X^[*4E1]2.1^(%>A_##XGW>J7ZZ'KTJR2NI-O=$ $[1DJ_;H#@^W.<UZC
MK=[I^GZ+=W&J/&MDL3"42=&!'W<=R>F.]?+'A/3;G6/%%M9V.Y97WE2/X0$)
MZT#/JG5=*LM;TV;3]0@6>VF&&1OT(/8CUKPOQ+\%=9L)WFT)UU"U)RL;,$E4
M>AS@-]1^5?0-%,1\NGPIX^E3[&VG:PT738Q;9^IQ75>%O@GJ%S.EQXCE6TMP
M03;Q.&D?V)'"C\S]*]XHI6 K6NGVEEI\=A;6\<=I&GEK"H^4+Z5Q>L>"+F.<
MSZ4X=,Y$3-AE^A/6N]HKGQ.$I8F-JBVZ]3IPV+JX:5Z;WZ=#RC5-!\2WP,MG
M-JFE:F>'EMW;R;CCK(%/#<?>&<]QWKE8OA3XVU[5 VN7>V-3@W-Q<^<<?[(R
M3^!Q7T#15TJ4J<>5R;]2*U6-27,HJ/IL>$>+_A'JS:E:Q>';%)+&"U2,R/,B
ML[Y8LQR1R<UZ:VBW[?"[^Q/*7[?_ &4+;R]XQYGE[<9Z=>]=53)98X(GEE<)
M&@RS$\ 5KHC)7>B/(?AAX \0^&/%<E_JEK'%;M:O&&696.XE2. ?8UZ1XJ\/
M0^*/#EWI,TAB\X I(!G8X.0<?4?EFM![^TBM4N7N8E@?&V0L,'/3!J2XN(;2
M!IKB58HEQEV. ,\4N:-MQ\DNQ\[3?!SQC:7)^S);2A3\LL5P%S^>#7HWB/P'
M>^./"^GRZDB6'B*TC\LN6#I)ZY*YX/4>F3UKO;74[&]D*6MU%,X&2$;) I+C
M5=/M)O)N+R&*3&=KN <5/M(<O-S*WJBO95.;EY7?T9\Z+X"^('AZZ9K&TO8F
MZ>;97 PP_P" G/YU?B\#_$GQ(PAU*:\2W)^9KZ[.T?\  <D_I7T.CK(@=&#*
MPR"#D$4R"XAN59H9%D56*DJ<X(ZBKT(LSR6_^"\-MX*FM=/D6YULNLOGR#:&
MQG,:_P!T<GZD#/M6^%&E^*?#FKW.GZCH=RNF78_>.^W;&X!PW)Y!'!Q[>E>M
MW&JZ?:SB">\ACE/\+. 1]?2K$L\4$#3RR*D2C)<G@"I4XN]GMN4X35KK?8\7
M\7?!2=[N6\\,RQ>4Y+&SE;:4/HC="/8XQZFN9A\/?$_20+>VCUF)%X"PW)*C
MZ8;%?1TD\4,!GDD58E&XN3P!33=VX$),R8G($1W??SR,>M-N*ZB49/9'SLOP
M[^(/B.9#J27&T'B2_NLA?PR3^0KUOP'\.[+P7"\YE^U:E,NV2<K@*O\ =4=A
M[]\5UMU>VMBBO=3QPJQP"YQDTEK?6M\K-:SQS*IP2ASBES1YN6^H^27+S6T[
MEBBBBK("BBB@ HHHH **** "L_75+:#?J 23 XP/I116=57IR7D_R9I1=JD7
MYK\T<E?Z'/!H0F,SO;1B)[: 9)1G*[\_KCZFNB\7*S^&;H*"3E. ,_QK117%
M[",(5%'K%?DSO]O.I4IN723_ #1'X>NXYYYD%^MT^T$ 61@VC///?J*K7=U9
MVGBBZ-]$722W14'DF3<>>. :**RYV\-&?5/U[]_4U]G%8J4.CCZ=NWH:'AJW
MFM])(EC>%7E=XHGZQH3P#_GO3?#*LMC=!@1_I<IY'O1179&FH2IQ71/]#AE5
M<XU)/JU^IF6D]EIIO;;5;-Y+N6=VY@,GGJ3QM./TK6\1#?X:NPB'F,87'/4=
MJ**PA'W*M/HKK;79O7[SHFTZE*IU=GOINEIVV#65+>%KE0"2;?&!]!6$MG=V
M%_I%J%:2Q,RS1.<DQ$K\R'VR<BBBJKTE*?-?5)?^E(6'K.$.6VC<O_26:/BT
ME8].<2>6%N03)Y7F;1@\[>]7= N8[BTDVW0N65^7%L8.W QW[\T44DVL8UW7
*Z#<4\"GV?ZG_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !( ,(# 2(  A$! Q$!_\0
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MT+<GL*:?#'QF@3[4GB2&68<^1YZG\,%-M 'M6!G.!GUJMJ=V=/TF\O50.UO
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M^"*** /3Z\S^+W@O6O&$6C+HT,,AM9)6E\V4)@,%QCUZ&BB@#TJ-2L2*>H4
MUQ?Q3\-:GXJ\'_V;I,<;W/VF.3$DFP;1G//XT44 <GXR^'GB+6OAWX6T:R@M
MVO=.C"W"M.%4'R]O![\UZU8Q/!I]M#( 'CB56P>X !HHH YKXE:!J'B;P1=:
M7IB1O=221,JR/L&%<$\_05=\#:3=Z%X)TG2[]46ZMH-DBHVX Y/0]Z** +?B
M:QGU3PMJMA:JK7%S:2Q1AC@%F4@9/;DUS7PI\+ZGX4\(S:=K$427#W;RA8Y
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3,#HJCLHR?J3110!V=%%% '__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
